Recently, Synthgene Biotech (hereinafter referred to as “Synthgene”), Areterna’s parent company, received a confirmation letter from the United States Food and Drug Administration (FDA) for one of our core mRNA raw material products – CAP5 – which have...
FOR IMMEDIATE RELEASE Gaithersburg, MD (July 2nd, 2024) — Areterna LLC, a company with a mission to democratize mRNA vaccine by supplying low-cost GMP raw materials, today announced plans to offer veterinary mRNA vaccine development service to its customers in the US...
In the intricate realm of mRNA therapeutics manufacturing, the meticulous selection of raw materials plays a pivotal role in ensuring the safety, efficacy, and ethical integrity of the final product. One crucial consideration in this process is the sourcing of animal...
To ensure effective in vivo delivery, mRNA vaccines rely on not only optimized antigen sequences but also a robust delivery system capable of overcoming extracellular barriers, facilitating endosomal escape, and evading intracellular immune responses. Lipid...
In recent years, mRNA vaccines and drugs have received widespread attention around the world. Areterna LLC is proud to introduce Fluc-eGFP mRNA (Catalog number: 11013-CAP), a cutting-edge tool to accelerate your mRNA research. This mRNA encodes both eGFP and...
